Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. more
Time Frame | IMUX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.2% | -1.8% | -0.77% |
1-Month Return | -1.63% | -3.48% | 0.71% |
3-Month Return | -20.39% | -7.2% | 8.81% |
6-Month Return | -4.72% | -1.54% | 12.32% |
1-Year Return | 2.54% | 8.39% | 30.57% |
3-Year Return | -86.83% | 6.07% | 29.21% |
5-Year Return | -86.28% | 44.07% | 91.95% |
10-Year Return | -99.85% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 50.00K | 39.00K | 85.00K | 77.00K | 111.00K | [{"date":"2019-12-31","value":45.05,"profit":true},{"date":"2020-12-31","value":35.14,"profit":true},{"date":"2021-12-31","value":76.58,"profit":true},{"date":"2022-12-31","value":69.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (50.00K) | (39.00K) | (85.00K) | (77.00K) | (111.00K) | [{"date":"2019-12-31","value":-5000000,"profit":false},{"date":"2020-12-31","value":-3900000,"profit":false},{"date":"2021-12-31","value":-8500000,"profit":false},{"date":"2022-12-31","value":-7700000,"profit":false},{"date":"2023-12-31","value":-11100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 37.03M | 48.97M | 91.67M | 86.52M | 99.22M | [{"date":"2019-12-31","value":37.32,"profit":true},{"date":"2020-12-31","value":49.35,"profit":true},{"date":"2021-12-31","value":92.38,"profit":true},{"date":"2022-12-31","value":87.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (37.03M) | (48.97M) | (91.67M) | (119.49M) | (99.22M) | [{"date":"2019-12-31","value":-3703200000,"profit":false},{"date":"2020-12-31","value":-4897100000,"profit":false},{"date":"2021-12-31","value":-9166500000,"profit":false},{"date":"2022-12-31","value":-11948800000,"profit":false},{"date":"2023-12-31","value":-9922300000,"profit":false}] |
Total Non-Operating Income/Expense | 2.21M | 5.01M | (1.21M) | 122.00K | 8.69M | [{"date":"2019-12-31","value":25.4,"profit":true},{"date":"2020-12-31","value":57.7,"profit":true},{"date":"2021-12-31","value":-13.98,"profit":false},{"date":"2022-12-31","value":1.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (34.93M) | (44.02M) | (92.94M) | (120.41M) | (93.61M) | [{"date":"2019-12-31","value":-3493300000,"profit":false},{"date":"2020-12-31","value":-4401700000,"profit":false},{"date":"2021-12-31","value":-9294500000,"profit":false},{"date":"2022-12-31","value":-12040700000,"profit":false},{"date":"2023-12-31","value":-9361200000,"profit":false}] |
Income Taxes | (107.00K) | (58.00K) | (151.00K) | 33.89M | - | [{"date":"2019-12-31","value":-0.32,"profit":false},{"date":"2020-12-31","value":-0.17,"profit":false},{"date":"2021-12-31","value":-0.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (34.83M) | (43.96M) | (92.79M) | (154.30M) | - | [{"date":"2019-12-31","value":-3482600000,"profit":false},{"date":"2020-12-31","value":-4395900000,"profit":false},{"date":"2021-12-31","value":-9279400000,"profit":false},{"date":"2022-12-31","value":-15429600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (34.93M) | (44.02M) | (92.94M) | (120.41M) | (93.61M) | [{"date":"2019-12-31","value":-3493300000,"profit":false},{"date":"2020-12-31","value":-4401700000,"profit":false},{"date":"2021-12-31","value":-9294500000,"profit":false},{"date":"2022-12-31","value":-12040700000,"profit":false},{"date":"2023-12-31","value":-9361200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (34.83M) | (43.96M) | (92.79M) | (154.30M) | (93.61M) | [{"date":"2019-12-31","value":-3482600000,"profit":false},{"date":"2020-12-31","value":-4395900000,"profit":false},{"date":"2021-12-31","value":-9279400000,"profit":false},{"date":"2022-12-31","value":-15429600000,"profit":false},{"date":"2023-12-31","value":-9361200000,"profit":false}] |
EPS (Diluted) | (3.81) | (2.85) | (3.93) | (3.77) | (2.11) | [{"date":"2019-12-31","value":-380.5,"profit":false},{"date":"2020-12-31","value":-285,"profit":false},{"date":"2021-12-31","value":-393,"profit":false},{"date":"2022-12-31","value":-377,"profit":false},{"date":"2023-12-31","value":-211,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMUX | |
---|---|
Cash Ratio | 2.53 |
Current Ratio | 2.71 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMUX | |
---|---|
ROA (LTM) | -90.90% |
ROE (LTM) | -216.24% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMUX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.36 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.64 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMUX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.80 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.21 |
Immunic Inc (IMUX) share price today is $1.21
Yes, Indians can buy shares of Immunic Inc (IMUX) on Vested. To buy Immunic Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMUX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Immunic Inc (IMUX) via the Vested app. You can start investing in Immunic Inc (IMUX) with a minimum investment of $1.
You can invest in shares of Immunic Inc (IMUX) via Vested in three simple steps:
The 52-week high price of Immunic Inc (IMUX) is $2.11. The 52-week low price of Immunic Inc (IMUX) is $0.97.
The price-to-earnings (P/E) ratio of Immunic Inc (IMUX) is
The price-to-book (P/B) ratio of Immunic Inc (IMUX) is 2.80
The dividend yield of Immunic Inc (IMUX) is 0.00%
The market capitalization of Immunic Inc (IMUX) is $118.90M
The stock symbol (or ticker) of Immunic Inc is IMUX